Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism TLR7 antagonists(Toll like receptor 7 antagonists), TLR8 antagonists(Toll like receptor 8 antagonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H32N6O |
InChIKeySNFVHLQYHFQOEP-UHFFFAOYSA-N |
CAS Registry2171019-55-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Systemic Lupus Erythematosus | Phase 2 | RO | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | CL | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | PL | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | IN | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | CO | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | US | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | BR | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | IE | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | AR | 11 Oct 2021 | |
Systemic Lupus Erythematosus | Phase 2 | FR | 11 Oct 2021 |
Not Applicable | - | - | zocrzcuybb(wcwjdcemkg) = All treatment-emergent AEs were mild and resolved spontaneously. There were no concerning abnormal laboratory test results, including tests of hepatic function and no serious AEs, deaths, or AEs leading to discontinuation. brczqcwmgr (pjslfqmluo ) | - | 09 Nov 2021 |